Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are severe drug reactions associated with high mortality and multiple incapacitating sequelae. In the past 20 years, two large multinational case control studies, published in 1995 and 2008, had identified different degrees of drug association with SJS/TEN: ‘strongly associated’, ‘associated’, ‘suspected’ and ‘not suspected’ medications.
The aim of this study was to check the adequacy of mention of risk of SJS/TEN in the drug dictionaries most widely used by physicians in five European countries.
In each country one expert investigator looked at the most widely used drug dictionary (2009 edition) for mentions of risk of SJS/TEN. This was done for a predefined list of medications with a different degree of risk. The presence and clarity or absence of warning was compared with available evidence provided by published results from case–control studies.
The five countries participating in the RegiSCAR group: Austria, France, Germany, The Netherlands and the UK.
A total of 3,268 drug descriptions of medications for systemic use were analysed, including all brands of 14 ‘strongly associated’ drugs, 5 ‘associated’ drugs and 12 widely used drugs with no established association. Discrepancies were found by country, and between descriptions for different brands of the same generic. Among 522 descriptions of 14 ‘strongly associated’ drugs, only 5 did not mention the risk. For the 1,013 descriptions of ‘associated’ drugs, 3 % did not mention the risk. One-third of ‘not suspected’ drugs contained a specific or less specific warning (e.g. bullous cutaneous eruption). Warnings for ‘strongly associated’ medications were often as imprecise as those for ‘not suspected’ drugs.
Information on the risk of SJS/TEN in drug dictionaries needs improvement to enhance the quality of advice given by general physicians and to raise the understanding of risk by patients.
- Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–8. CrossRef
- Mockenhaupt M. The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7:803–13. CrossRef
- Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49:769–73. CrossRef
- Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40. CrossRef
- Oplatek A, Brown K, Sen S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27:26–33. CrossRef
- Shapiro S, Dunne J, Kaufman D, editors. Monitoring and assessment of adverse drug effects. Geneva: CIOMS/WHO; 1986.
- Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7. CrossRef
- Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44. CrossRef
- Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther. 2010;88:60–8. CrossRef
- Arzneimittelinformation. Innsbruck: MedEval GmbH Ed; 2009.
- Vidal Ed. Issy les Moulineaux: Vidal; 2009.
- Rote list. Frankfurt: Rote Liste® Service-GmbH Ed; 2009.
- Farmacotherapeutisch Kompas 2009, ed. AC van Loenen. Diemen: College voor zorgverzekeringen (CVZ); 2008.
- British National Formulary. London: BMJ Group & Pharmaceutical Press; 2009.
- Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf. 2010;9:15–21. CrossRef
- Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134–9. CrossRef
- Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99–107. CrossRef
- Genin E, Schumacher M, Roujeau JC, et al. Genome-wide association study of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52. CrossRef
- Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29:706–12. CrossRef
- Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323–7. CrossRef
- Cheung A, Sacks D, Dewa CS, et al. Pediatric prescribing practices and the FDA black-box warning on antidepressants. J Dev Behav Pediatr. 2008;29:213–5. CrossRef
- Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170:96–103. CrossRef
- Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk?
Volume 36, Issue 8 , pp 681-686
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Henri Mondor Hospital, University Paris-Est Créteil, Créteil, France
- 2. Medical University, Innsbruck, Austria
- 3. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 4. Dokumentationszentrum schwerer Hautreaktionen (dZh), University Medical Center, Freiburg, Germany
- 5. King’s College Hospital, London, UK
- 6. Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France
- 7. 19 avenue d’Alembert, 92160, Antony, France